Published in Gastroenterol Clin Biol on January 01, 1992
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 6.88
Albumin messenger RNA as a marker of circulating hepatocytes in hepatocellular carcinoma. Gastroenterology (1994) 2.62
Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut (2005) 2.39
Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med (1994) 2.31
Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion. Hepatology (1993) 2.23
Detection of c-Ki-ras mutation by PCR/RFLP analysis and diagnosis of pancreatic adenocarcinomas. J Natl Cancer Inst (1993) 2.16
Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology (1998) 2.06
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology (2000) 2.04
Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol (2001) 1.98
A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med (1991) 1.92
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology (1998) 1.85
Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology (1988) 1.79
Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology (1988) 1.76
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur J Cancer Clin Oncol (1988) 1.74
Association of chronic interstitial cystitis, protein-losing enteropathy and paralytic ileus with seronegative systemic lupus erythematosus: case report and review of the literature. Clin Nephrol (1992) 1.66
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology (1997) 1.63
Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis. Am J Pathol (1999) 1.58
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology (2001) 1.55
Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J Hepatol (2001) 1.54
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
[Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis]. Gastroenterol Clin Biol (2000) 1.44
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol (2010) 1.42
Elevation of CA 125 in patients with benign and malignant ascites. Cancer (1987) 1.42
Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis. Liver Transpl Surg (1999) 1.41
[Definition and criteria of imputability of drug-induced acute pancreatitis]. Gastroenterol Clin Biol (1992) 1.40
Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol (1993) 1.39
Choledocho-ureteral anastomosis in the rat. A new experimental model of long-term, total, internal bile diversion. J Hepatol (1993) 1.39
Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem (1996) 1.38
PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest (2000) 1.32
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat (2007) 1.29
Prothrombin time in liver failure: time, ratio, activity percentage, or international normalized ratio? Hepatology (1996) 1.28
Hepatic stellate cell proliferation is an early platelet-derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab Invest (2001) 1.27
Factors predictive of the response to interferon in patients with chronic hepatitis C. J Hepatol (1994) 1.26
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat (2011) 1.24
[Coagulation disorders after reinjection of concentrated ascitic fluid. Preliminary study]. Med Chir Dig (1973) 1.22
A new clinical condition linked to a novel mutation in lamins A and C with generalized lipoatrophy, insulin-resistant diabetes, disseminated leukomelanodermic papules, liver steatosis, and cardiomyopathy. J Clin Endocrinol Metab (2003) 1.20
Fetal microchimerism in primary biliary cirrhosis. J Hepatol (2000) 1.20
Survival, anatomic, and functional long-term results in choroidal and ciliary body melanoma after ruthenium brachytherapy (15 years' experience with beta-rays). Am J Ophthalmol (2004) 1.20
[Coagulation disorders during continuous reinjections of ascitic fluid. Fibrinolysis or intravascular coagulation?]. Nouv Presse Med (1973) 1.19
Fatal hepatitis after herbal tea. Lancet (1992) 1.15
Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet (1998) 1.12
Risk factors for hepatitis C virus infection in hepatitis C virus antibody ELISA-positive blood donors according to RIBA-2 status: a case-control survey. Hepatology (1993) 1.12
Pharmacological effect of somatostatin on bile secretion in man. Digestion (1989) 1.11
Chronic cholestatic diseases. J Hepatol (2000) 1.11
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6 and tumor necrosis factor-alpha production by monocytes. Hepatology (1992) 1.06
Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther (1990) 1.04
Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol (2000) 1.04
Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol (1994) 1.03
Uveal effusion induced by topical travoprost in a patient with Sturge-Weber-Krabbe syndrome. J Fr Ophtalmol (2008) 1.03
Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies. Hepatology (1985) 1.03
Effects of proton beam irradiation on uveal melanomas: a comparative study of Ki-67 expression in irradiated versus non-irradiated melanomas. Br J Ophthalmol (2000) 1.02
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol (1995) 1.01
[Gonococcal conjunctivitis complicated by perforating corneal abscess in an adult]. J Fr Ophtalmol (2007) 1.01
Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol (1990) 1.00
Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology (1987) 0.99
Serum hyaluronan as a marker of liver fibrosis. J Hepatol (1995) 0.97
Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology (2006) 0.96
Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology (1993) 0.96
Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepatogastroenterology (1983) 0.95
Rapid and sensitive liquid chromatographic assay of mefenamic acid in plasma. Ther Drug Monit (1992) 0.95
Interposition mesocaval shunt for chronic primary occlusion of the hepatic veins. Surg Gynecol Obstet (1979) 0.95
Bile acid transport and regulating functions in the human biliary epithelium. Hepatology (2001) 0.95
Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem Res Toxicol (2001) 0.95
Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology (1999) 0.95
[Rectal adenocarcinoma in association with lymphoma ("collision tumor")]. Gastroenterol Clin Biol (1990) 0.95
Absence of anti-LKM-1 antibody in hepatitis C viral infection in the United States of America. J Viral Hepat (1995) 0.94
Effect of lysine acetylsalicylate on biliary lipid secretion in dogs. Clin Sci Mol Med (1975) 0.93
Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology (1990) 0.92
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther (1996) 0.92
Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology (1996) 0.92
Survival after a first episode of spontaneous bacterial peritonitis. Prognosis of potential candidates for orthotopic liver transplantation. J Gastroenterol Hepatol (1995) 0.91
beta- and alpha-Adrenoceptor antagonism by medroxalol in healthy volunteers: relationship to dose and plasma concentration. J Cardiovasc Pharmacol (1982) 0.90
Circulating albumin messenger RNA in hepatocellular carcinoma: results of a multicenter prospective study. Hepatology (1997) 0.90
[Hepatic peliosis. Clinical and paraclinical aspects apropos of 6 cases of unusual etiology]. Med Chir Dig (1977) 0.90
[Celiac disease in adults. (48 cases) I. Anatomo-clinical, biological and radiological study; its course under a non-gluten diet]. Arch Fr Mal App Dig (1975) 0.90
[Tienilic acid-induced hepatitis associated with liver/kidney microsomal antibody (author's transl)]. Nouv Presse Med (1980) 0.89
[Interferon alpha-2a treatment of 26 patients with chronic non-A non-B hepatitis. Predictive factors of response]. Gastroenterol Clin Biol (1990) 0.89
[Renal toxicity of the association: gentamicin/furosemide. One case (author's transl)]. Nouv Presse Med (1978) 0.89
Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens (1986) 0.89
Cytological aspiration of intraocular retinoblastoma in an 11-year-old boy. Diagn Cytopathol (1998) 0.89
Wagner vitreoretinal degeneration with genetic linkage refinement on chromosome 5q13-q14. Graefes Arch Clin Exp Ophthalmol (1999) 0.89